176 related articles for article (PubMed ID: 20798121)
1. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
Ponticelli C; Locatelli F
Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
[No Abstract] [Full Text] [Related]
2. [Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease].
Joly D
Med Sci (Paris); 2011 Mar; 27(3):249-51. PubMed ID: 21447293
[No Abstract] [Full Text] [Related]
3. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
4. [Autosomal dominant polycystic kidney disease].
Horie S
Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
[No Abstract] [Full Text] [Related]
5. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
6. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Levey AS; Stevens LA
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
[No Abstract] [Full Text] [Related]
8. mTOR inhibitors in polycystic kidney disease.
Watnick T; Germino GG
N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
[No Abstract] [Full Text] [Related]
9. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Braun WE
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
[No Abstract] [Full Text] [Related]
10. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Grantham JJ; Bennett WM; Perrone RD
N Engl J Med; 2011 Jan; 364(3):286-7; author reply 287-9. PubMed ID: 21247328
[No Abstract] [Full Text] [Related]
11. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
13. Do mTOR inhibitors still have a future in ADPKD?
Perico N; Remuzzi G
Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768
[No Abstract] [Full Text] [Related]
14. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
Soliman A; Zamil S; Lotfy A; Ismail E
Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
He Q; Lin C; Ji S; Chen J
Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
[TBL] [Abstract][Full Text] [Related]
18. mTOR signaling in polycystic kidney disease.
Ibraghimov-Beskrovnaya O; Natoli TA
Trends Mol Med; 2011 Nov; 17(11):625-33. PubMed ID: 21775207
[TBL] [Abstract][Full Text] [Related]
19. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
[TBL] [Abstract][Full Text] [Related]
20. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
Rapoport J
QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
